Bacillus amyloliquefaciens TL106 protects mice against enterohaemorrhagic Escherichia coli O157:H7‐induced intestinal disease through improving immune response, intestinal barrier function and gut microbiota

Aims This study evaluated the effects of Bacillus amyloliquefaciens TL106, isolated from Tibetan pigs’ faeces, on the growth performance, immune response, intestinal barrier function, morphology of jejunum, caecum and colon, and gut microbiota in the mice with enterohaemorrhagic Escherichia coli (EHEC)‐induced intestinal diseases. Methods and Results In all, 40 female C57BL/6J mice were randomly divided into four groups: mice fed a normal diet (Control), mice oral administration of TL106 daily (Ba), mice challenged with EHEC O157:H7 on day 15 (O157) and mice oral administration of TL106 daily and challenged with EHEC O157:H7 on day 15 (Ba+O157). The TL106 was administrated to mice for 14 days, and mice were infected with O157:H7 at day 15. We found that TL106 could prevent the weight loss caused by O157:H7 infection and alleviated the associated increase in pro‐inflammatory factors (TNF‐α, IL‐1β, IL‐6 and IL‐8) and decrease in anti‐inflammatory factor (IL‐10) in serum and intestinal tissues of mice caused by O157:H7 infection (P